Safety and tolerability of combined treatment with moclobemide and SSRIs: A systematic study of 50 patients

International Clinical Psychopharmacology

Volumn 11, Issue 3, 1996, Pages 187-191

  Hawley, C J ^a   Quick, S J ^a   Ratnam, S ^b   Pattinson, H A ^a   McPhee, S ^c  

^a QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^b CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^c UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Combination; Fluoxetine; Moclobemide; Paroxetine; SSRI

Indexed keywords

FLUOXETINE; MOCLOBEMIDE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG COMBINATION; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; MYOCLONUS; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029844411     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199609000-00005     Document Type: Article

References (22)

1. Austin MPV, Souza FGM and Goodwin GM (1991) Lithium augmentation in antidepressant resistant patients. A quantitative analysis. British Journal of Psychiatry, 159, 510-514.
2. Bakish D, Hooper CL, West DL, Miller C, Blanchard A and Bashir F (1995) Moclobemide and specific serotonin re-uptake inhibitor combination treatment of resistant anxiety and depressive disorders. Human Psychopharmacology, 10, 105-109.
3. Boyer WF and Feighner JP (1991) Pharmacokinetics and drug interactions. In: Selective Serotonin Re-uptake Inhibitors (Eds WF Boyer and JP Feighner), pp. 85-86. John Wiley & Sons, Chichester.
4. Chaimowitz GA, Links PS, Padgett RW and Carr AC (1991) Treatment resistant depression: a survey of practice habits of Canadian psychiatrists. Canadian Journal of Psychiatry, 36, 353-356.
5. Dingemense J (1993) An update of recent moclobemide interaction data. International Clinical Psychopharmacology, 7, 167-180.
6. Elkin I, Shea T, Watkins JT et al. (1989) National Institute of Mental Health Treatment of Depression Collaborative Research Program: general effectiveness of treatments. Archives of General Psychiatry, 46, 971-982.
7. Fawcett J (1994) Antidepressants: partial response in chronic depression. British Journal of Psychiatry, 165 (suppl 26), 37-41.
8. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication ADM 76-338, pp. 217-222. National Institute of Mental Health, Rockville, Md.
9. Hawley CJ, Pattinson HA and Ratnam S (1995) A preliminary study of combined therapy with moclobemide and SSRIs. Journal of Psychopharmacology, 9 (suppl), A22.
10. Joffe RT, Singer W, Levitt AJ and MacDonald C (1993) A placebo controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressant in unipolar refractory depression. Archives of General Psychiatry, 50, 387-393.
11. Katona CL (1991) Refractory depression. In: The uses of fluoxetine in clinical practice (Ed HI Freeman), Royal Society of Medicine Services International Congress and Symposium Series, No. 183. Royal Society of Medicine Services Limited.
12. Katona CL, Abou-Saleh M, Harrison DA et al. (1995) Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. British Journal of Psychiatry, 166, 80-86.
13. Keller MB (1994). Depression: a long term illness. British Journal of Psychiatry, 165 (suppl 26), 9-15.
14. Marley E and Wozniak KM (1984a) Interactions of a nonselective monoamine oxidase inhibitor, phenelzine, with inhibitors of 5-hydroxytryptamine, dopamine and noradrenaline re-uptake. Journal of Psychiatric Research, 18, 173-189.
15. Marley E and Wozniak KM (1984b) Interactions of non-selective monoamine oxidase inhibitors, tranylcypromine and nialamide, with inhibitors of 5-hydroxytryptamine, dopamine and noradrenaline re-uptake. Journal of Psychiatric Research, 18, 191-203.
16. Nelsen MR and Dunner DL (1993) Treatment resistance in unipolar depression and other disorders: diagnostic concerns and treatment possibilities. Psychiatric Clinics of North America, 16, 541-566.
17. Nelson JC (1993) Combined treatment strategies in psychiatry. Journal of Clinical Psychiatry, 54 (suppl), 42-49.
18. Neuvonen PJ, Pohjola SS, Tacke U and Vuori E (1993) Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet, 342, 1419.
19. Preskorn SH (1995) Comparison of the tolerability of buproprion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. Journal of Clinical Psychiatry, 56 (suppl 6), 12-21.
20. Radomski JW, Dursun SM and Reveley MA (1995) Toxic serotonin syndrome (TSS): an update and revised diagnostic criteria. Journal of Psychopharmacology, 1 (suppl), A21.
21. Stein G and Bernadt M (1993) Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. British Journal of Psychiatry, 162, 634-640.
22. Sternbach H (1991) The serotonin syndrome. American Journal of Psychiatry, 148, 705-713.